91
COAPT - The purpose of the Cardiovascular Outcomes Assessment of the MitraClip ® Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation ( COAPT ) trial is to confirm the safety and effectiveness of the MitraClip System for the treatment of moderateto severe or severe functional mitral regurgitation ( FMR ) in symptomatic heart failure subjects who are treated per standard of care and who have been determined by the site ’ s local heart team as not appropriate for mitral valve surgery . Principal investigator : Robert F . Hebeler , Jr ., MD .
COAPT / CAS - The objective of this study is to evaluate the MitraClip ® NT System for the treatment of clinically significant functional mitral regurgitation ( FMR ) in symptomatic heart failure subjects who are treated per standard of care and who have been determined by the site ’ s local heart team as not appropriate for mitral valve surgery . Principal investigator : Robert F . Hebeler , Jr ., MD .
COREVALVE EUS - Expanded use of corevalve to include SAVR , dialysis patients , low cardiac output patients . Principal investigator : Robert Stoler , MD .
CTO – A multi-center registry of chronic total occlusion interventions . Principal Investigator : James Choi , MD .
CS-03 TENDYNE – Tendyne valve system for severe mitral regurgitation . Principal investigator : Robert F . Hebeler , Jr ., MD .
CSWG / SHOCK 1000 – Shock 1000 multi-center registry . Principal investigator : Shelley Hall , MD .
DAPA ACT HF - A multi-center , randomized , double-blind , parallel group , placebo-controlled trial to evaluate the effect of in-hospital initiation of dapagliflozin on clinical outcomes in patients with heart failure with reduced ejection fraction who have been stabilized during hospitalization for acute heart failure . Principal investigator : Amarinder Bindra , MD .
DIAMOND – A multi-center , double-blind , placebocontrolled , randomized withdrawal , parallel group study of Patiromer for the management of hyperkalemia in subjects receiving Renin- Angiotensin-Aldosterone System Inhibitor ( RAASi ) medications for the treatment of heart failure . Principal investigator : Amarinder Bindra , MD .
EARLY TAVR - A prospective , controlled , multi-center study . Patients will be randomized 1:1 to receive either transcatheter aortic valve replacement ( TAVR ) with the Edwards SAPIEN 3 THV or clinical surveillance ( CS ). Patients are stratified by whether or not they are able to perform a treadmill stress test ; in addition , patients who are screened for enrollment but have a positive stress test will be followed in a registry to collect data on subsequent treatment and mortality , as applicable . Principal investigator : Robert Stoler , MD .
ECMO-CARD CCC - COVID-19 Critical Care Consortium : Cardiac Sub-Study . Principal investigator : Dan M . Meyer , MD .
EVAHEART - This is a prospective , multi-center , unblinded , randomized , controlled , and noninferiority study comparing the EVA2 LVAS to the most recent magnetically levitated centrifugal LVAS ( HM3 LVAS ). Principal investigator : Dan M . Meyer , MD .
EVINACUMAB - The primary objective of this study is to demonstrate the reduction of low-density lipoprotein cholesterol by Evinacumab . It is an openlabel study to evaluate the long-term safety and efficacy of Evinacumab in patients with homozygous familial hypercholesterolemia . Primary investigator : Robert Gottlieb , MD , PhD .
EVOLUT R / XL – This study evaluates the efficacy and safety of the Evolut R and XL aortic valve replacement . Principal investigator : Robert Stoler , MD .
EVOLVE 4.5 / 5.0 - A US post-approval study to prove the safety and effectiveness of the Synergy 4.50 / 5.0 mm Everolimus-Eluting Platinum Chromium Coronary Stent System for treatment of atherosclerotic lesions . Principal investigator : Robert Stoler , MD .
EVOLVE 48 - A prospective multi-center single arm trial to assess the safety and effectiveness of the SYNERGY™ 48 mm Everolimus-Eluting Platinum Chromium Coronary Stent System ( SYNERGY™ Stent System ) for the treatment of subjects with atherosclerotic lesion ( s ). Principal investigator : Robert Stoler , MD .
EXCEED - A prospective , single-arm , controlled , multicenter study to establish the safety and effectiveness of the CENTERA THV system in intermediate risk patients who have symptomatic , severe , calcific , aortic stenosis requiring aortic valve replacement . Principal investigator : Robert Stoler , MD .
Baylor Scott & White Heart and Vascular Hospital | Clinical Trials and Research